Summary
Over the past twenty years, breast cancer has come to be much more commonly regarded and treated as a systemic disease. Conventional chemotherapy and endocrine therapy used according to schedules that are tolerable to patients are generally effective and often induce worthwhile responses; nevertheless, the responses in general have a median duration of less than a year, and these therapies are rarely if ever curative. Continued efforts to use available agents with mere modifications of schedule and intensity seem unlikely to substantially improve upon the modest success already achieved. Rather, we desperately need radically new schedules, new agents (especially non-myelosuppressive agents), and new approaches (e.g. monoclonal antibody targeting of drugs, toxins, or radionuclides, perhaps combined with tumor sensitizing agents such as heat). It is our hope that consideration of some of these issues will encourage others to be bolder in devising the next generation of clinical trials.
Similar content being viewed by others
References
Baum M: The curability of breast cancer. Brit Med J I: 439–442, 1976
Stoll BA: Breast cancer — endocrine therapy.In Stoll BA (ed): Endocrine Therapy in Malignant Disease. WB Saunders, London, 1972, pp 111–236
Henderson IC, Canellos GP: Cancer of the breast — the past decade. N Engl J Med 302:17–30, 1980
Carbone PP, Bauer M, Band P, Tormey D: Chemotherapy of disseminated breast cancer. Current status and prospects. Cancer 39:2916–2229, 1977
Carter SK: Chemotherapy of breast cancer: current status.In Heuson JC, Mattheim WH, Rozencweig M (eds): Breast Cancer Trends in Research and Treatment. Raven Press, New York, 1976, pp 193–215
Carter SK: The interpretation of trials: combined hormonal therapy and chemotherapy in disseminated breast cancer. Breast Cancer Res Treat 1:43–51, 1981
Corden BJ, Hill JB, Collins J, Ozols RF: High dose cisplatinum in hypertonic saline: absence of nephrotoxicity and pharmacokinetics. Proc ASCO Abstract C132, 1983, San Diego, California
Jones RB, Norton L, Bhardwaj S, Mass T, Holland JF: Single agent adriamycin for metastatic breast cancer. A steep dose-response relationship.
Cadman EC, Davis L, Heimer R: Enhanced 5-fluorouracil nucleotide formation following methotrexate. Science 205:1135–1137, 1979
Santen RJ, Worgul TJ, Samojlik E, Boucher AE, Lipton A, Harvey H: Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. Cancer Res 42:3397–3402, 1982
Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562, 1979
Legha SS, Buzdar AU, Smith T, Swenerton KD, Hortobagyi GN, Blumenschein GN: Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer 46: 438–445, 1980
Clark GM, McGuire WL: Progesterone receptors and human breast cancer. Breast Cancer Res Treat 3:157–163, 1983
Greenspan EM, Fieber M, Lesnick G, Edelman S: Response of advanced breast carcinoma to the combination of the antimetabolite methotrexate and the alkylating agent thiotepa. J Mt Sinai Hosp (New York) 30:246–267, 1963
Carbone PP, Tormey DC: Combination chemotherapy for advanced disease.In McGuire WL (ed): Breast Cancer — Advances in Research and Treatment, Vol I. Plenum, New York, 1977, pp 165–215
Bonadonna G, Valagussa P: Chemotherapy of breast cancer — current views and results. Int J Rad Oncol (in press)
Jones SE, Durie BGM, Salmon SE: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36:90–97, 1975
Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bidey GP, Freireich EJ: Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Int Med 91:847–852, 1979
Decker DA, Ahmann DL, Bisel HF, Edmonson HL, Hahn RG, O'Fallon JR: Complete responders to chemotherapy in metastatic breast cancer. JAMA 242:2075–2079, 1979
Malik R, Blumenschein GR, Legha SS, Hortobagyi GN, Buzdar A, Yap HY, Hill S, Bodey GP: A randomized trial of high dose 5-fluorouracil, doxorubicin and cyclophosphamide vs conventional FAC regimen in metastatic breast cancer. Proc ASCO 1982#C303, St Louis, Missouri
Hirshault Y, Kesselhein H: Prolonged remissions of metastatic breast cancer achieved with a six drug regimen of relatively low toxicity. Cancer 51:1998–2004, 1983
Creech RH, Catalano RB, Mastrangelo MJ, Engstrom PA: An effective low dose intermittent cyclophosphamide, methotrexate and 5-fluorouracil treatment regimen for metastatic breast cancer. Cancer 35:1101–1107, 1973
Muss HB, White DR, Cooper MR, Richards F, Spurr CL: Combination chemotherapy in advanced breast cancer. Arch Intern Med 36:90–97, 1977
Tormey DC, Falkson G, Simon RM, Blom J, Bull JM, Lippman ME, Li S, Cassidy JG, Falkson H: A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 2:247–256, 1979
Bull JM, Tormey DC, Li SH: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41:1649–1657, 1978
Cadman E, Gewirtz AM: Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancer. Cancer 47:2552–2555, 1981
Allegra JC, Woodcock TM, Richman SP: A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer. Breast Cancer Res Treat 2: 93–100, 1982
Perrault DJ, Ehrlichman C, Hasselback R, Tannock I, Boyd N: Sequenced methotrexate and 5-fluorouracil in refractory metastatic breast cancer: a phase II study. Proc ASCO 1983 Abstract #C389, San Diego, California
Ahmann FR, Jones SE: Chemo-hormonal therapy in metastatic breast cancer. Proc 26 Annual Clin Conf MD Anderson Hospital (in press)
Lippman ME: Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three? Breast Cancer Res Treat 3:117–127, 1983
Kiang DT, Frenning DH, Gay J, Kennedy BJ: Combination of hormone and chemotherapy in advanced breast cancer. Cancer 47:452–456, 1981
Henderson IC, Gelman R, Canellos GP, Frei E: Prolonged disease-free survival in advanced breast cancer treated with ‘Super CMF’ adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue. Cancer Treat Reports 65 (Suppl):67–75, 1981
Lippman ME, Cassidy JC, Wesley M, Young RC: A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol (submitted)
Smith HS, Hackett AJ, Lan S, Stampfer MR: Use of an efficient method for culturing human mammary epithelial cells to study adriamycin sensitivity. Cancer Chemother Pharmacol: 237–244, 1981
Von Hoff DD, Cowan J, Harris G, Reisdorf G: Human tumor cloning: feasibility and clinical correlations. Cancer Chemother Pharmacol 6:265–271, 1981
Yap HY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP: Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Int Med 95:694–697, 1981
Falkson G, Falkson HC: Phase II trial of spirogermanium for treatment of advanced breast cancer. Cancer Treat Rep 67:189–190, 1983
Forastiere AA, Hakes TB, Wittes JT, Wittes RE: Cisplatin in the treatment of metastatic breast cancer. Am J Clin Oncol 5:243–247, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lippman, M.E. An assessment of current achievements in the systemic management of breast cancer. Breast Cancer Res Tr 4, 69–77 (1984). https://doi.org/10.1007/BF01806388
Issue Date:
DOI: https://doi.org/10.1007/BF01806388